Clinical Trial Update: A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

View source ↗

Summary

Post-authorization, long-term real-world safety study of Ozanimod for relapsing-remitting multiple sclerosis. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Zeposia (ozanimod) (ozanimod)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Sclerosis, Relapsing-Remitting | Status: ACTIVE_NOT_RECRUITING